TY - JOUR
T1 - Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
AU - Simonsen, Anja Hviid
AU - Herukka, Sanna-Kaisa
AU - Andreasen, Niels
AU - Baldeiras, Ines
AU - Bjerke, Maria
AU - Blennow, Kaj
AU - Engelborghs, Sebastiaan
AU - Frisoni, Giovanni B
AU - Gabryelewicz, Tomasz
AU - Galluzzi, Samantha
AU - Handels, Ron
AU - Kramberger, Milica G
AU - Kulczyńska, Agnieszka
AU - Molinuevo, Jose Luis
AU - Mroczko, Barbara
AU - Nordberg, Agneta
AU - Oliveira, Catarina Resende
AU - Otto, Markus
AU - Rinne, Juha O
AU - Rot, Uroš
AU - Saka, Esen
AU - Soininen, Hilkka
AU - Struyfs, Hanne
AU - Suardi, Silvia
AU - Visser, Pieter Jelle
AU - Winblad, Bengt
AU - Zetterberg, Henrik
AU - Waldemar, Gunhild
N1 - Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2017/3
Y1 - 2017/3
N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.
AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with dementia. The recommendations were developed by a multidisciplinary working group based on the available evidence and consensus from focused discussions for (i) identification of Alzheimer's disease (AD) as the cause of dementia, (ii) prediction of rate of decline, (iii) cost-effectiveness, and (iv) interpretation of results. The working group found sufficient evidence to support a recommendation to use CSF AD biomarkers as a supplement to clinical evaluation, particularly in uncertain and atypical cases, to identify or exclude AD as the cause of dementia. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Operational recommendations for the interpretation of ambiguous CSF biomarker results were also provided.
KW - Alzheimer Disease
KW - Amyloid beta-Peptides
KW - Biomarkers
KW - Databases, Bibliographic
KW - Humans
KW - Peptide Fragments
KW - tau Proteins
KW - Journal Article
KW - Review
U2 - 10.1016/j.jalz.2016.09.008
DO - 10.1016/j.jalz.2016.09.008
M3 - Review article
C2 - 28341065
VL - 13
SP - 274
EP - 284
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
SN - 1552-5260
IS - 3
ER -